Coegin Pharma AB (NGM: COEGIN)

Coegin Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cost of Revenue	0.02	0.02	-	-	-
Gross Profit	-0.02	-0.02	-	-	-
Selling, General & Admin	24.96	25.21	34.94	31.91	48.6
Other Operating Expenses	-0.38	-0.43	-2.97	-4.74	-2.34
Operating Expenses	27.6	27.8	34.69	27.18	46.28
Operating Income	-27.62	-27.82	-34.69	-27.18	-46.28
Interest Expense	-0.35	-0.05	-0.22	-	-
Interest & Investment Income	0.03	0.02	0.01	-	0.04
Currency Exchange Gain (Loss)	-0.14	-0.14	-0.33	0.04	-0.01
Pretax Income	-28.08	-27.98	-35.24	-27.15	-46.24
Net Income	-28.08	-27.98	-35.24	-27.15	-46.24
Net Income to Common	-28.08	-27.98	-35.24	-27.15	-46.24
Shares Outstanding (Basic)	10	9	7	6	1
Shares Outstanding (Diluted)	10	9	7	6	1
Shares Change (YoY)	33.30%	34.42%	15.36%	354.98%	-
EPS (Basic)	-2.89	-3.04	-5.14	-4.59	-35.39
EPS (Diluted)	-2.89	-3.04	-5.14	-4.59	-35.39
Free Cash Flow	-20.63	-22.02	-38.23	-21.49	-7.78
Free Cash Flow Per Share	-2.12	-2.39	-5.57	-3.61	-5.95
EBITDA	-24.6	-24.8	-31.97	-27.17	-46.25
D&A For EBITDA	3.02	3.02	2.72	0.01	0.02
EBIT	-27.62	-27.82	-34.69	-27.18	-46.28
Revenue as Reported	0.5	0.57	3.13	4.76	2.34

Source: S&P Capital IQ. Standard template. Financial Sources.